Europe · Business news · Corporate · 05 Oct 2026
EUUS Health Care
Genmab and AbbVie said the Phase 3 EPCORE DLBCL-2 trial met its main goal: epcoritamab added to the standard R-CHOP regimen cut the risk of disease progression or death by 51% against R-CHOP alone (hazard ratio 0.49, p below 0.0001) in newly diagnosed diffuse large B-cell lymphoma patients with IPI scores of 2 to 5. The companies said they would take the data to regulators. Genmab shares rose about 9% in Copenhagen on Tuesday, to a three-year high according to Reuters, and were the STOXX 600's largest gainer.
Epcoritamab, sold as EPKINLY in the US and Japan and TEPKINLY in the EU, is approved so far for lymphoma that has returned after earlier treatment. A first-line label would open a much larger group of patients, and Genmab shares the drug's economics with AbbVie. The companies call it the first bispecific antibody combination to show a significant progression-free survival gain in frontline DLBCL, which bears on rival bispecifics from other drugmakers. No sales figures or filing dates were given, and approval is not assured. Europe's healthcare index rose 1.4%.
Reported by GlobeNewswire — “Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma” ↗ on 05 Oct 2026.
Official series on 05 Oct 2026 or the last day before it, and the latest observation.
Fresenius Medical Care runs 3,513 dialysis clinics treating about 290,000 patients, and under Giza it finished a programme that took about €1.2 billion out of its cost base. The change comes with five days' notice…
The move in French debt matters most to banks and insurers that hold it and to French companies whose borrowing costs follow the sovereign; it reverses part of the sell-off that took the CAC 40 to a six-month low on…
The increase answers activist investor Palliser Capital, which argued the first price undervalued the company and asked for at least €60 a share; the new terms are still well below that, so minority holders now choose…
The split shows the bond selloff is now a country story inside Europe. Higher French government yields raise funding costs for French banks, insurers and heavily indebted companies and lower the value of the sovereign…
All European business stories · Every market · What changed today